Dr. Lund received an honors degree in Biochemistry from the University of Dundee, Scotland in 1990 and a Ph.D. in Veterinary Immunology and Pathology from the Royal “Dick” Veterinary College at the University of Edinburgh, Scotland in 1994. He trained with world-renowned immunologists during his post-doctoral fellowship in viral immunology from 1994-1997 at the BBSRC Institute for Animal Health. Dr. Lund was recruited to the USC Department of Neurology as a senior research fellow in 1997 to the study efficacy of a novel vaccine for the treatment of multiple sclerosis. In 1999 Dr. Lund was appointed to the faculty in the Department of Neurology at USC as a visiting Assistant Professor and was subsequently appointed as Assistant Professor in 2004.
Dr. Lund’s research primarily focuses on the role of the immune system, not only in the pathogenesis and accrual of pathology in the central nervous system, but also in tissue repair and neuroplasticity. His work is conducted both in animal models of disease and in MS patients. Current research includes assessing the potential role of the renin-angiotensin system on disease progression in MS and animal models, and in collaboration with faculty in the school of pharmacy and the school of medicine assessing the capacity of therapeutic intervention by manipulating the protective arm of this critical biological system. Dr. Lund is also assessing the effect of exercise in disease prevention and recovery, testing the possibility that exercise alters immune status to be more neuroprotective and less damaging. Dr. Lund is also actively involved in numerous clinical trials and studies with colleagues at USC, assessing possible modes of action of new and approved MS therapies, and studying the effects of MS drugs on the immune system in MS patients.
The National Multiple Sclerosis Society, US Department of Defense, USC-CTSI, numerous pharmaceutical companies and private foundations have supported Dr. Lund’s research. He is a member of the British Society for Immunology, the Society for General Microbiology and the Federation of Clinical Immunology Societies and serves as a member of the University of Southern California, Radiation Safety Committee and the Institutional Animal Care and Use Committee.
Maternal Inflammation Disrupts Fetal Neurodevelopment via Increased Placental Output of Serotonin to the Fetal Brain. J Neurosci. 2016 Jun 1; 36(22):6041-9. View in: PubMed
In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells. J Neurol Sci. 2014 Nov 15; 346(1-2):66-74. View in: PubMed
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod. J Neuroimmunol. 2013 Oct 15; 263(1-2):108-15. View in: PubMed
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013 Oct; 70(10):1315-24. View in: PubMed
The dual role of CXCL8 in human CNS stem cell function: Multipotent neural stem cell death and oligodendrocyte progenitor cell chemotaxis. Glia. 2011 Dec; 59(12):1864-78. View in: PubMed
Multiple sclerosis in Hispanics: a study of clinical disease expression. Mult Scler. 2011 Aug; 17(8):1010-6. View in: PubMed
The role of exercise in facilitating basal ganglia function in Parkinson's disease. Neurodegener Dis Manag. 2011 Apr 1; 1(2):157-170. View in: PubMed
Role of IL-23 in mobilization of immunoregulatory nitric oxide- or superoxide-producing Gr-1+ cells from bone marrow. Free Radic Biol Med. 2009 Aug 15; 47(4):357-63. View in: PubMed
Measuring apoptosis in neural stem cells. Methods Mol Biol. 2008; 438:227-41. View in: PubMed
Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J Leukoc Biol. 2007 May; 81(5):1205-12. View in: PubMed
Gene regulation networks related to neural differentiation of hESC. Gene Expr. 2007; 14(1):23-34. View in: PubMed
Association of MBP peptides with Hsp70 in normal appearing human white matter. J Neurol Sci. 2006 Nov 15; 249(2):122-34. View in: PubMed
Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol. 2004 Oct; 155(1-2):161-71. View in: PubMed
Immunological aspects of secondary progressive multiple sclerosis. Mult Scler. 2002 Feb; 8(1):83-4. View in: PubMed
Resistance to glucocorticoid-induced apoptosis in PLP peptide-specific T cell clones from patients with progressive MS. J Neuroimmunol. 2000 Sep 22; 109(2):197-210. View in: PubMed
T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol. 2000 Jul 24; 107(2):130-9. View in: PubMed
Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000 Jun 13; 54(11):2147-50. View in: PubMed
Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 2000; 6(5A):563-75. View in: PubMed